(R)-(-)-Repaglinide

(R)-(-)-Repaglinide is a medication used to treat type 2 diabetes. It is an oral hypoglycemic drug that helps to lower blood glucose levels by stimulating insulin secretion from the pancreas. The drug is sold under the brand name Prandin, and is available in both tablet and capsule forms. It is often prescribed alongside a healthy diet and exercise regimen to help manage blood sugar levels in patients with type 2 diabetes. The chemical name for (R)-(-)-Repaglinide is (S)-(+)-2-ethoxy-4-(2-(3-methyl-1-(2-(1-piperidinyl)phenyl)butylamino)-2-oxoethyl)benzoic acid. It is a chiral compound, meaning it has a non-superimposable mirror image. The (R)-(-) enantiomer is the active form of the drug, while the (S)-(+) enantiomer is inactive. The drug works by binding to ATP-sensitive potassium channels on the surface of pancreatic beta cells, which stimulates the release of insulin. This leads to a decrease in blood glucose levels. The drug has a relatively short half-life, meaning it is quickly metabolized and eliminated from the body. (R)-(-)-Repaglinide is generally well-tolerated, but some patients may experience side effects such as hypoglycemia, weight gain, and gastrointestinal symptoms. It is important for patients taking this medication to monitor their blood glucose levels regularly and to follow their healthcare provider's instructions for use.